DRL has expanded its strategic collaboration with Amgen
Dr Reddy’s Laboratories (DRL) has collaborated with Amgen, a leading biotechnology company, to market and distribute three of Amgen’s medicines in India in therapy areas of oncology and osteoporosis. Under the terms of the collaboration, DRL will commercialise XGEVA (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India.
In 2015, DRL announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval of and launch Amgen’s Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India. The collaboration combines Amgen’s innovative therapies with DRL’s deep understanding of patient and physician needs in India.
MV Ramana, Executive VP and Head of Emerging Markets and India Business, DRL said, “We are delighted to continue our relationship with Amgen as it strengthens our constant endeavour to enhance patient’s access to novel treatment options across therapy areas. These medicines provide unique treatment options to physicians to address unmet medical need in the area of oncology and osteoporosis.”